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Dear Editor, 
 
We thank Steptoe et al for highlighting their research in the ocular health of Ebola Virus Disease 
(EVD) survivors [1]. We agree that the interpretation and value of subjective experiences can be 
challenging. Disability is a complex phenomenon that is not always easily amenable to objective 
biological quantification. The self-reported physical limitations and mental health problems provide 
an insight into the perception of health by the EVD survivors and remains a valuable tool to assess 
the quality of life.  
 
In Liberia the lack of correlation between self-reported ophthalmic symptoms and diagnosis of 
uveitis in EVD survivors further highlights the need for screening and research [2]. Blindness was 
reported in 38% of EVD survivors with uveitis in this study. We recognize the potential challenges of 
cataract surgery reported by Steptoe et al, and look forward to seeing further results from the EVICT 
II study in Sierra Leone, which has reported to date that cataract surgery was safe and effective in 
EVD survivors, leading to meaningful restoration of vision [3].  
 
The gravity of ocular disease and the need of ophthalmological expertise in the rehabilitation of the 
survivors in West Africa are now widely reported in the media [4]. We concur that health system 
strengthening with the integration of survivor care may ensure long-term sustainable rehabilitation, 
and acknowledge the large unmet need for healthcare in the general population. However, EVD 
survivors remain at greater risk of visual disability, and would benefit from the Ebola survivor 
specific international funding.  
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